CO6170359A2 - Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas - Google Patents
Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicasInfo
- Publication number
- CO6170359A2 CO6170359A2 CO09041439A CO09041439A CO6170359A2 CO 6170359 A2 CO6170359 A2 CO 6170359A2 CO 09041439 A CO09041439 A CO 09041439A CO 09041439 A CO09041439 A CO 09041439A CO 6170359 A2 CO6170359 A2 CO 6170359A2
- Authority
- CO
- Colombia
- Prior art keywords
- dihydropirazolones
- cardiovascular
- replaced
- treatment
- hematological diseases
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 208000014951 hematologic disease Diseases 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Compuesto de formula (I) en la que R1 representa un grupo heteroarilo de fórmulas en las que * significa el sitio de unión con el anillo de dihidropirazolona, A significa en cada aparición individual C-R4 o N, representando como máximo dos miembros de anillo A simultáneamente N, y E significa O, S o N-R5,R2 representa un grupo heteroarilo de fórmulas en las que# significa el sitio de unión con el anillo de dihidropirazolona,G significa en cada aparición individual C-R6 o N, representando como máximo dos miembros de anillo G simultáneamente N, J significa O, S o N-R7, y L significa en cada aparición individual C-R8 o N, representando como máximo dos miembros de anillo L simultáneamente N, ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006050516A DE102006050516A1 (de) | 2006-10-26 | 2006-10-26 | Substituierte Dihydropyrazolone und ihre Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6170359A2 true CO6170359A2 (es) | 2010-06-18 |
Family
ID=38734870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09041439A CO6170359A2 (es) | 2006-10-26 | 2009-04-24 | Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas |
Country Status (41)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| DE102008020113A1 (de) * | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
| DE102006050515A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
| DE102006050513A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substitiuierte Dihydropyrazolone und ihre Verwendung |
| DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| EP2294066B9 (en) | 2008-04-28 | 2015-03-11 | Janssen Pharmaceutica, N.V. | Benzoimidazoles as prolyl hydroxylase inhibitors |
| MY179093A (en) * | 2008-12-29 | 2020-10-27 | Sanofi Sa | Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators |
| FR2940651B1 (fr) * | 2008-12-29 | 2013-05-03 | Sanofi Aventis | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif |
| FR2949466A1 (fr) * | 2009-08-28 | 2011-03-04 | Sanofi Aventis | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif |
| CA2748413A1 (fr) | 2008-12-29 | 2010-07-08 | Sanofi | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique |
| IT1393337B1 (it) | 2009-03-06 | 2012-04-20 | Italiana Sint Spa | Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina |
| DE102010044131A1 (de) * | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituiertes Natrium-1H-pyrazol-5-olat |
| GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
| GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
| ES2689481T3 (es) | 2011-10-25 | 2018-11-14 | Janssen Pharmaceutica Nv | Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico |
| EP2628722A1 (en) | 2012-02-16 | 2013-08-21 | Bayer CropScience AG | CF3O-containing enaminoketones and their utilization for the preparation of CF3O-containing pyrazoles |
| CA2869130A1 (en) | 2012-03-30 | 2013-10-03 | Daiichi Sankyo Company, Limited | 4-alkanoylamino-3-pyrazolone derivatives |
| SG11201407043PA (en) * | 2012-05-08 | 2014-12-30 | Bayer Pharma AG | Method for the preparation of triazole compounds |
| CA2873674A1 (en) | 2012-05-29 | 2013-12-05 | Momentive Performance Materials Gmbh | Preparation of isocyanato silanes |
| CN105492433B (zh) | 2013-03-29 | 2018-11-23 | 武田药品工业株式会社 | 6-(5-羟基-1h-吡唑-1-基)烟碱酰胺衍生物和其作为phd抑制剂的用途 |
| EA032932B1 (ru) | 2013-10-17 | 2019-08-30 | Байер Фарма Акциенгезельшафт | Лекарственная форма, содержащая натрий-1-[6-(морфолин-4-ил)пиримидин-4-ил]-4-(1h-1,2,3-триазол-1-ил)-1н-пиразол-5-олат, и способ ее получения |
| US10065928B2 (en) | 2014-09-02 | 2018-09-04 | Sunshine Lake Pharma Co., Ltd. | Quinolinone compound and use thereof |
| CN107778262A (zh) * | 2016-08-24 | 2018-03-09 | 尹玉新 | 1,5‑双取代四氮唑类化合物及其制备方法和应用 |
| CN109694380B (zh) * | 2017-10-23 | 2022-09-27 | 中国医药研究开发中心有限公司 | 二氢吡唑啉酮类化合物及其制备方法和医药用途 |
| CN111825690B (zh) * | 2019-04-17 | 2022-09-27 | 中国医药研究开发中心有限公司 | 一种phd抑制剂的新晶型及其制备方法 |
| US11579118B2 (en) | 2019-06-03 | 2023-02-14 | Tdw Delaware, Inc. | Single point contact triaxial sensor head for an inline inspection tool |
| US10702525B1 (en) | 2019-09-04 | 2020-07-07 | United Arab Emirates University | Pyrimidine derivatives as anti-diabetic agents |
| US20230135152A1 (en) * | 2020-02-11 | 2023-05-04 | AcuraStem Incorporated | Pikfyve kinase inhibitors |
| MX2022010059A (es) | 2020-02-18 | 2022-08-25 | Bayer Ag | Nuevos compuestos de heteroaril-triazol como pesticidas. |
| JP2023518543A (ja) * | 2020-03-20 | 2023-05-02 | アケビア セラピューティクス インコーポレイテッド | Ｐｈｄ阻害剤化合物、組成物、及びそれらの使用 |
| EP3888684A1 (en) | 2020-03-31 | 2021-10-06 | Bayer Animal Health GmbH | Composition having improved voluntary acceptance |
| EP4138825A1 (en) | 2020-04-20 | 2023-03-01 | Akebia Therapeutics Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| WO2022251563A1 (en) | 2021-05-27 | 2022-12-01 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
| CN116120340B (zh) * | 2021-11-15 | 2023-10-31 | 艾立康药业股份有限公司 | 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE424016C (de) | 1923-05-20 | 1926-01-14 | Allg Vergasungs Ges M B H Fa | Schachtofen mit Schwelaufsatz zur Vergasung und Verschwelung bituminoeser Stoffe |
| FR1519069A (fr) | 1966-04-13 | 1968-03-29 | Geigy Ag J R | Dérivés du sulfanilamide et leur préparation |
| GR63123B (en) | 1975-12-11 | 1979-09-11 | Lilly Co Eli | Preparation process of novel 1,4-diphenyl-3-pyrazolin-5-ones |
| US4075003A (en) | 1975-12-11 | 1978-02-21 | Eli Lilly And Company | Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones |
| PL103509B1 (pl) * | 1976-09-20 | 1979-06-30 | Lilly Co Eli | Srodek chwastobojczy |
| US4663327A (en) * | 1984-05-23 | 1987-05-05 | Bayer Aktiengesellschaft | 1-heteroaryl-4-aryl-pyrazolin-5-ones |
| DE3443308A1 (de) | 1984-11-28 | 1986-05-28 | Bayer Ag, 5090 Leverkusen | 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel |
| DE3527157A1 (de) | 1985-07-30 | 1987-02-12 | Bayer Ag | 1-heteroaryl-4-aryl-pyrazol-derivate |
| DE4204919A1 (de) | 1992-02-19 | 1993-08-26 | Bayer Ag | Verfahren zur herstellung von 2-chlor-5-alkylaminomethyl-pyridinen |
| DE4240168A1 (de) | 1992-11-30 | 1994-06-01 | Bayer Ag | Cumarin-Derivate, Verfahren zu ihrer Herstellung und ihrer Verwendung |
| FR2725988B1 (fr) | 1994-10-24 | 1997-01-24 | Roussel Uclaf | Nouveaux derives de pyrazolones et pyrazoles acides, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
| JPH10306077A (ja) | 1997-05-07 | 1998-11-17 | Daiichi Rajio Isotope Kenkyusho:Kk | ビピラゾール誘導体並びにこれを有効成分とする医薬および試薬 |
| DE19909237A1 (de) | 1999-03-03 | 2000-09-07 | Merck Patent Gmbh | Pyrazol-3-on-derivate |
| CA2404128C (en) * | 2000-03-20 | 2011-01-04 | Peter Literati Nagy | Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| US6878729B2 (en) * | 2001-05-04 | 2005-04-12 | The Procter & Gamble Company | Medicinal uses of dihydropyrazoles |
| WO2002092573A2 (en) | 2001-05-16 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| AU2002359714B2 (en) | 2001-12-18 | 2006-12-21 | Merck Sharp & Dohme Corp. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| AU2003213673A1 (en) | 2002-03-01 | 2003-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7652033B2 (en) | 2003-03-27 | 2010-01-26 | Emory University | HIF-1 inhibitors |
| WO2004089303A2 (en) | 2003-04-03 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| JP2007527854A (ja) * | 2003-05-01 | 2007-10-04 | パナシア ファーマシューティカルズ インコーポレーテッド | 虚血関連状態の治療方法 |
| AU2004275694B2 (en) * | 2003-06-30 | 2008-03-06 | Bizbiotech Co., Ltd. | Compounds, compositions and methods |
| CA2614068A1 (en) * | 2004-06-29 | 2006-08-24 | Massachusetts Institute Of Technology | Methods and compositions related to the modulation of intercellular junctions |
| AT7634U1 (de) | 2004-06-29 | 2005-06-27 | Binder Co Ag | Detektiervorrichtung und sortiervorrichtung |
| DE102008020113A1 (de) * | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
| AU2006227729B2 (en) | 2005-03-16 | 2011-10-13 | Aventis Pharmaceuticals Inc. | Dipyrazoles as central nervous system agents |
| MX2007013263A (es) * | 2005-04-26 | 2008-01-22 | Neurosearch As | Novedosos derivados oxadiazol y su uso medico. |
| DE102005019712A1 (de) * | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| DE102006050516A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| DE102006050515A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
| DE102006050513A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substitiuierte Dihydropyrazolone und ihre Verwendung |
| DE102010044131A1 (de) | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituiertes Natrium-1H-pyrazol-5-olat |
-
2006
- 2006-10-26 DE DE102006050516A patent/DE102006050516A1/de not_active Withdrawn
-
2007
- 2007-10-12 ES ES11175197.0T patent/ES2621787T3/es active Active
- 2007-10-12 EP EP07818948.7A patent/EP2084151B1/de active Active
- 2007-10-12 DK DK12188156.9T patent/DK2546253T3/en active
- 2007-10-12 US US12/447,192 patent/US8389520B2/en active Active
- 2007-10-12 ES ES07818948T patent/ES2421454T3/es active Active
- 2007-10-12 BR BRPI0717367A patent/BRPI0717367B8/pt active IP Right Grant
- 2007-10-12 CA CA2667382A patent/CA2667382C/en active Active
- 2007-10-12 KR KR1020097010634A patent/KR101455879B1/ko active IP Right Grant
- 2007-10-12 DK DK07818948.7T patent/DK2084151T3/da active
- 2007-10-12 PL PL12188156T patent/PL2546253T3/pl unknown
- 2007-10-12 EP EP11175197.0A patent/EP2383269B1/de active Active
- 2007-10-12 CN CN2007800482623A patent/CN101631785B/zh active Active
- 2007-10-12 NZ NZ596583A patent/NZ596583A/xx unknown
- 2007-10-12 RU RU2009119431/04A patent/RU2469031C2/ru active
- 2007-10-12 NZ NZ576458A patent/NZ576458A/en unknown
- 2007-10-12 SG SG2011078359A patent/SG176421A1/en unknown
- 2007-10-12 ES ES12188156.9T patent/ES2534872T3/es active Active
- 2007-10-12 EP EP12188156.9A patent/EP2546253B1/de active Active
- 2007-10-12 PT PT121881569T patent/PT2546253E/pt unknown
- 2007-10-12 PL PL07818948T patent/PL2084151T3/pl unknown
- 2007-10-12 SI SI200731293T patent/SI2084151T1/sl unknown
- 2007-10-12 AU AU2007328052A patent/AU2007328052B2/en active Active
- 2007-10-12 UA UAA200905266A patent/UA98125C2/ru unknown
- 2007-10-12 JP JP2009533691A patent/JP5247712B2/ja active Active
- 2007-10-12 MY MYPI20091696A patent/MY169564A/en unknown
- 2007-10-12 RS RS20130347A patent/RS52924B/en unknown
- 2007-10-12 MX MX2009004324A patent/MX2009004324A/es active IP Right Grant
- 2007-10-12 CN CN201310122718.3A patent/CN103342696B/zh active Active
- 2007-10-12 PT PT78189487T patent/PT2084151E/pt unknown
- 2007-10-12 WO PCT/EP2007/008877 patent/WO2008067871A1/de active Application Filing
- 2007-10-25 TW TW102116012A patent/TWI561237B/zh active
- 2007-10-25 TW TW096139977A patent/TWI437991B/zh active
- 2007-10-25 PE PE2012000031A patent/PE20120635A1/es active IP Right Grant
- 2007-10-25 PE PE2011001768A patent/PE20120620A1/es active IP Right Grant
- 2007-10-25 TW TW104139543A patent/TW201630605A/zh unknown
- 2007-10-25 AR ARP070104726A patent/AR063392A1/es active IP Right Grant
- 2007-10-25 PE PE2007001451A patent/PE20080895A1/es not_active Application Discontinuation
- 2007-10-29 UY UY30663A patent/UY30663A1/es active IP Right Grant
-
2009
- 2009-04-10 TN TNP2009000132A patent/TN2009000132A1/fr unknown
- 2009-04-20 ZA ZA200902705A patent/ZA200902705B/xx unknown
- 2009-04-22 IL IL198289A patent/IL198289A/en active IP Right Grant
- 2009-04-23 GT GT200900095A patent/GT200900095A/es unknown
- 2009-04-23 HN HN2009000784A patent/HN2009000784A/es unknown
- 2009-04-23 CU CU20090066A patent/CU23743B7/es active IP Right Grant
- 2009-04-23 SV SV2009003236A patent/SV2009003236A/es unknown
- 2009-04-24 CR CR10750A patent/CR10750A/es unknown
- 2009-04-24 CO CO09041439A patent/CO6170359A2/es active IP Right Grant
- 2009-04-27 NO NO20091655A patent/NO343308B1/no unknown
- 2009-05-21 MA MA31909A patent/MA30914B1/fr unknown
-
2010
- 2010-07-13 HK HK10106809.6A patent/HK1140478A1/xx unknown
- 2010-10-12 JP JP2010229627A patent/JP5300813B2/ja active Active
-
2011
- 2011-05-26 CU CU2011000119A patent/CU24056B1/es active IP Right Grant
-
2012
- 2012-01-23 US US13/356,256 patent/US8653111B2/en active Active
- 2012-08-10 RU RU2012134284A patent/RU2611012C2/ru active
- 2012-09-13 IL IL221928A patent/IL221928A/en active IP Right Grant
-
2013
- 2013-02-18 US US13/769,513 patent/US8987261B2/en active Active
- 2013-03-26 PH PH12013500578A patent/PH12013500578B1/en unknown
- 2013-08-19 HR HRP20130779TT patent/HRP20130779T1/hr unknown
- 2013-08-21 CY CY20131100718T patent/CY1114272T1/el unknown
-
2014
- 2014-04-08 HK HK14103324.5A patent/HK1190153A1/xx not_active IP Right Cessation
- 2014-08-21 CR CR20140392A patent/CR20140392A/es unknown
-
2015
- 2015-02-04 US US14/613,367 patent/US9168249B2/en active Active
- 2015-04-10 HR HRP20150396TT patent/HRP20150396T1/hr unknown
- 2015-09-25 US US14/866,323 patent/US20160229858A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6170359A2 (es) | Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas | |
| UY29223A1 (es) | Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación | |
| CR8831A (es) | Compuestos y metodos para el tratamiento de dislipidemia | |
| GT201000023A (es) | Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met. | |
| EA201170884A1 (ru) | Производные пиперидина, пригодные в качестве антагонистов орексина | |
| CR11373A (es) | COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA | |
| DOP2009000227A (es) | Derivados de aril isoxazolina insecticidas | |
| ECSP066717A (es) | Compuestos de quinolina sustituidos | |
| BR112012018345A2 (pt) | "compostos de heteroarila, bem como composições e usos dos mesmos" | |
| DOP2010000047A (es) | Compuestos de pirazol y su uso como inhibidores de raf | |
| ECSP099581A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso | |
| NI200900071A (es) | Compuestos de pirozolina y su uso y composiciones farmacéuticas. pc 33496a. | |
| HN2008001393A (es) | Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| DK1940409T3 (da) | Nye lægemiddelkombinationer til behandling af åndedrætssygdomme | |
| MA32505B1 (fr) | 5-alcynyl-pyrimidines | |
| MA32723B1 (fr) | Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments | |
| ECSP088925A (es) | Nitrilos espirocíclicos como inhibidores de proteasa | |
| EA200602157A1 (ru) | Новые производные тетрагидропиридотиофена | |
| MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
| UY29264A1 (es) | Tiazolidinonas metasustituidas, su preparación y su uso como medicamento | |
| CU20100111A7 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares | |
| GT201100300A (es) | Piperidinas sustituidas | |
| DOP2006000024A (es) | Tiazolidinonas, su preparación y su uso como medicamento | |
| ATE521609T1 (de) | Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs | |
| UY30046A1 (es) | Nuevos derivados de furopirimidina acíclicos sustitiudos y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |